Familial hypercholesterolemia (FH) is a condition with very high concentrations of low-density lipoprotein (LDL) cholesterol and high risk of ischemic heart disease including myocardial infarction. However, there is limited and contradictory information on whether FH and high LDL cholesterol per se confer high risk of ischemic stroke. We tested the hypotheses that individuals in the general population with FH and/or high LDL cholesterol have higher risk of ischemic stroke.
H
eterozygous familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder with a prevalence of 1:200 to 1:250 in white people, [1] [2] [3] [4] and the most common FH mutations are found in LDLR and APOB genes, encoding the low-density lipoprotein (LDL) receptor and its ligand apolipoprotein B. Individuals with FH have lifelong highly elevated LDL cholesterol leading to premature ischemic heart disease (IHD) including myocardial infarction. 5 Index cases of FH are generally recognized in primary care guided by a family history of premature IHD and hypercholesterolemia, and among patients with premature IHD in hospital settings using various FH diagnostic criteria; however, FH is severely underdiagnosed and undertreated, with <1% of FH individuals being diagnosed in most countries. 1, 5 The use of genetic testing for diagnosing FH varies considerably throughout the world. 6 Early identification and treatment of FH index cases, and their families, with lipid-lowering therapies such as statins, are crucial in preventing premature IHD. 5 Whether individuals with FH and genetically high concentrations of LDL cholesterol also have an increased risk of ischemic stroke is currently undetermined, as only limited and contradictory evidence is available. [7] [8] [9] [10] [11] [12] Determining this would be of prognostic value and would highlight an additional need for identification and treatment of individuals with FH.
We therefore tested the hypotheses that individuals in the general population with FH and/or high LDL cholesterol have higher risk of ischemic stroke. For this purpose, we used FH causative mutations not prone to confounding by other ischemic stroke risk factors. Additionally, we used the three resources for clinical FH criteria: Simon Broome, 13 MEDPED (Make Early Diagnosis to Prevent Early Death), 14 and DLCN (Dutch Lipid Clinic Network). 5 Last, we performed observational and genetic Mendelian randomization studies to determine if high LDL cholesterol, per se, has a causal effect on ischemic stroke risk.
METHODS
The studies were conducted in accordance with the Declaration of Helsinki and approved by local institutional review boards and Danish ethical committees (H-KF-01-144/01; KF-100.2039/91; KF-01-144/01). Written informed consent was obtained from all individuals. Individuals were white and of Danish descent, and none appeared in more than 1 study. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Copenhagen General Population Study
The CGPS (Copenhagen General Population Study) is a prospective cohort study initiated in 2003. Individuals aged 20 to 100 years were invited randomly from the general population surrounding Copenhagen using the national Danish Civil Registration System (43% response rate). Data were from a selfreported questionnaire reviewed together with an examiner on the day of study attendance, a physical examination, and blood samples for biochemical analyses and DNA extraction. A total of 106 412 individuals were genotyped for FH causative mutations (flowchart in Figure I in the online-only Data Supplement). For prospective observational analyses, 1649 individuals were excluded due to ischemic or hemorrhagic stroke prior to study attendance, leaving 104 763 individuals.
Copenhagen City Heart Study
The CCHS (Copenhagen City Heart Study) is a prospective study of the general population initiated in 1976 to 1978 with follow-up examinations in 1981 to 1983, 1991 to 1994, 2001 to 2003, and 2011 to 2015. Individuals were recruited and examined as in the CGPS. A total of 10 372 individuals from the 1991 to 1994 and the 2001 to 2004 examinations with baseline measurements of LDL cholesterol and information on genetic variants were included as an independent cohort for confirmation of the results obtained in the CGPS, and for the Mendelian randomization analysis.
Diagnostic Criteria for FH
Different diagnostic criteria for FH exist. The primary focus of this study was on genetically defined FH based on the 4 most common FH mutations in the population of Copenhagen: LDLR W23X(rs267607213), W66G(rs121908025) and W556S, and APOB R3500Q(rs5742904). These 4 mutations account for ≈39% of FH mutations in the Copenhagen population, and other previously reported mutations have low prevalence. 2 Additionally, FH was defined using clinical criteria based on the Simon Broome, MEDPED, and DLCN criteria (Methods and Table I in the online-only Data Supplement). The 3 different clinical criteria were modified as done previously, 2, 15 as not all information was available in the CGPS (Table I in 
Clinical Perspective
What Is New?
• In this study of 116 784 individuals from the general population, there was no association between familial hypercholesterolemia mutations and ischemic stroke risk.
• In a Mendelian randomization analysis, also including common genetic variants, there was no causal effect of high low-density lipoprotein cholesterol on risk of ischemic stroke.
What Are the Clinical Implications?
• Low-density lipoprotein cholesterol is traditionally considered a risk factor for ischemic stroke and statins reduce ischemic stroke risk.
• The predominant goal of targeting low-density lipoprotein cholesterol lowering, in those with and without familial hypercholesterolemia, is likely to reduce myocardial infarction, rather than stroke. until November 2014; not a single person was lost to followup while those emigrating (n=396) were censored at the date of emigration. Ischemic stroke events were validated by 2 independent medical doctors blinded to test results, as previously described. 18 In the validation process, hospital records and records from general practitioners were requested, and a diagnosis of ischemic stroke was confirmed using the World Health Organization definition of stroke, ie, if the individual had focal neurological symptoms lasting more than 24 hours or leading to death, not due to hemorrhagic stroke or subarachnoid hemorrhage. To distinguish between infarctions and hemorrhages, computed tomography or magnetic resonance imaging scan, autopsy, spinal fluid examination, or surgical description was necessary. If the individual had symptoms that met the criteria of the stroke definition, but the scan did not show an infarction or hemorrhage, the event was diagnosed as ischemic stroke.
A diagnosis of myocardial infarction (ICD-8: 410; ICD-10: I21-I22) was also ascertained using the national Danish Patient Registry and the national Danish Causes of Death Registry.
Biochemical Analyses
Blood samples were drawn nonfasting as recommended. 19 LDL cholesterol was calculated using the Friedewald equation when triglycerides were ≤4.0 mmol/L (352 mg/dL) and otherwise measured directly (Konelab, Thermo Fisher Scientific). Total cholesterol, high-density lipoprotein cholesterol, triglycerides, and glucose were measured using colorimetric assays (Konelab). LDL and total cholesterol in individuals receiving lipid-lowering therapy were multiplied by 1.43, corresponding to a 30% average reduction in LDL cholesterol, 20 as done previously.
2,15

Genotypes
TaqMan assays (Applied Biosystems) were used to genotype for LDLR W23X (rs267607213), W66G(rs121908025) and W556S, and APOB R3500Q(rs5742904) mutations. PCSK9 R46L(rs11591147), R237W(rs148195424), I474V(rs562556) and E670G(rs505151), NPC1L1 -18(rs41279633) and V1296V(rs217434), and HMGCR (rs17238484) were genotyped by either TaqMan assays or a competitive allele-specific polymerase chain reaction system (KASPar; LGC Genomics). All genotypes appeared to be in Hardy-Weinberg equilibrium (P >0.05), and call rates were >99%. Sequencing of randomly selected individuals was used to verify genotyping.
Other Covariates
Hypertension was blood pressure ≥140/90 mm Hg (≥135/85 mm Hg for diabetics), and/or use of antihypertensive medication. Diabetes mellitus was self-reported diabetes, use of antidiabetic medication, nonfasting plasma glucose >11 mmol/L (>198 mg/dL), or hospitalization with diabetes (ICD-8: 249-250; ICD-10: E10-E11, E13-E14). Atrial fibrillation (ICD-8: 427.93-427.94; ICD-10: I48.0-I48.9) and IHD (ICD-8: 410-414; ICD-10: I20-I25) before baseline were based on information from the national Danish Patient Registry. Family history of IHD and hypercholesterolemia, and personal history of premature peripheral vascular disease, were selfreported. Body mass index was measured: weight (kg) divided by measured height squared (m 2 ). Lipid-lowering therapy, acetylsalicylic acid therapy, smoking status (never, former, or current), cumulative smoking (pack-years), alcohol consumption (drinks per week; 1 drink=12 g alcohol), fruit intake (1-3 fruits/mo, 1-2/wk, 3-4/wk, 5-6/wk, 1/d, 2-3/d, >3/d), physical activity in leisure time (<2 h/wk, 2-4 h/wk, >4 h/wk, or 2-4 h exhausting exercise/wk, >4 h exhausting exercise/wk), and income were all self-reported. Income was in four categories based on the annual household income before tax: <200 000 DKK, 200 000 to 399 999 DKK, 400 000 to 799 999 DKK, and ≥800 000 DKK (1DKK≈0.15USD).
Statistical Analyses
Data were analyzed using Stata/SE 13.1. Missing information on continuous covariates for adjustment was imputed based on age and sex using multivariable linear regression, while separate categories were generated for missing information on categorical covariates (<0.9% of covariates were missing); if only individuals with complete data were included, results were similar to those reported.
In genetic analyses for the CGPS, follow-up began either at the initiation of the Danish registers in 1977 or at date of birth, whichever came latest. Estimated cumulative incidences of ischemic stroke and myocardial infarction for carriers versus noncarriers of an FH mutation were plotted using postestimates from competing risk regression, as described by Fine and Gray, 21 with death and emigration as competing risks. P values were obtained similarly. Estimated cumulative incidences of ischemic stroke and myocardial infarction for individuals with and without hypertension were plotted as described above as an additional positive control. In a sensitivity analysis, individuals with diabetes before baseline or during follow-up were excluded, and cumulative incidences of ischemic stroke and myocardial infarction were obtained as described above.
Cox proportional hazards regression with left truncation and delayed entry using age as the underlying time scale (thereby adjusting for age) 22 was used to obtain hazard ratios (HR) for ischemic stroke. Individuals were censored at death (n=5402), emigration (n=396), or end of followup. The proportional hazards assumption was assessed using Schoenfeld residuals, and no major violations were detected. Multivariable adjustment in observational analyses was for baseline factors with known association with risk of ischemic stroke that were not included in the clinical FH criteria, that is, age (as time-scale), sex, plasma triglycerides, body mass index, hypertension, systolic blood pressure, diabetes, plasma glucose, atrial fibrillation, lipid-lowering therapy, acetylsalicylic acid therapy, smoking status, cumulative smoking, alcohol consumption, fruit intake, physical activity in leisure time, and income. To maximize statistical power, ORIGINAL RESEARCH ARTICLE the DLCN definite and probable groups were combined in all analyses. To account for possible competing risks, a competing-risk regression model, as described above, was also conducted in a sensitivity analysis. In another sensitivity analysis, association between FH by Simon Broome criteria and risk of ischemic stroke was examined in strata of other risk factors for ischemic stroke. P for interaction was from a likelihood ratio test.
In exploratory analyses, we also examined the possible cause of the difference in association between the different FH criteria and risk of ischemic stroke by stratifying by IHD before baseline, as inclusion of a personal history of premature IHD is the primary difference between the DLCN and the two other clinical FH criteria.
Association between stepwise higher concentrations of LDL cholesterol and risk of ischemic stroke stratified by personal IHD before baseline, not taking clinical FH into account, was tested by Cox proportional hazards regression as described above.
To confirm our results in an independent cohort, cumulative incidences of ischemic stroke and myocardial infarction for carriers versus noncarriers of an FH mutation in the CCHS were obtained as described for the CGPS.
For the Mendelian randomization analysis of the association between LDL cholesterol and ischemic stroke, we generated a weighted genotype score using 11 genetic mutations and variants not in linkage disequilibrium that were individually associated with LDL cholesterol concentrations: LDLR W23X(rs267607213), W66G (rs121908025) and W556S, APOB R3500Q(rs5742904), PCSK9 R46L(rs11 591147), R237W(rs148195424), I474V(rs562556) and E670G(rs505151), NPC1L1 -18(rs41279633) and V1296V (rs217434), and HMGCR(rs17238484). The genotype score was weighted by the percentage increase in LDL cholesterol per allele compared to the genotype with the lowest LDL cholesterol for each variant. For each individual, a genotype score was calculated by summation of the percentage increase in LDL cholesterol across the 11 variants. The weighted genotype score was divided into 5 groups, creating groups with as extreme LDL cholesterol as possible, with enough statistical power. These groups were used in instrumental variable analysis, where causal risk ratios for ischemic stroke were estimated by the multiplicative generalized methods of moments estimator, and F-statistics and R 2 as a percentage were estimated from the first-stage of a two-stage least squares regression. 23 Cox proportional hazards regression, multivariable adjusted as described above, was used for observational estimates for a 1 mmol/L (39 mg/ dL) higher LDL cholesterol.
To test whether the combined weighted genotype score groups were associated with stepwise higher risk of ischemic stroke, we used Cox proportional hazards regression, described as above, and adjusted for age (as underlying time scale), sex, lipid-lowering therapy, and date of birth; since this was an analysis of genotypes, follow-up started from 1977 or date of birth, whichever came latest.
As a sensitivity analysis, we excluded individuals in the CGPS (n=1) with possible periprocedural stroke due to coronary artery bypass grafting or percutaneous coronary intervention from all analyses; however, results were similar to those shown.
RESULTS
Baseline characteristics of individuals from the CGPS by FH mutation status are shown in the Table. Individuals with an FH mutation had higher total and LDL cholesterol concentrations, had lower triglycerides, received more lipid-lowering and acetylsalicylic acid therapy, and had a higher prevalence of premature IHD, family history of cardiovascular disease, and family history of hypercholesterolemia compared to individuals without an FH mutation. Of 106 412 individuals, 11 were heterozygous for LDLR W23X(rs267607213), 54 heterozygous for LDLR W66G(rs121908025), 3 heterozygous for LDLR W556S, and 117 heterozygous for APOB R3500Q(rs5742904); that is, 0.17% were heterozygous for 1 of the 4 most common mutations that in Denmark account for ≈39% of all FH mutations. This suggests that 0.45% or 1:224 are heterozygous for an FH mutation in the Danish general population. None were homozygous or compound heterozygotes.
Cumulative Incidences of Ischemic Stroke and Myocardial Infarction by FH Mutations and Hypertension
Association between FH mutations and ischemic stroke risk was tested in 106 412 individuals from the CGPS, who were followed for 3 977 463 person-years with a median follow-up of 38 years (range: 1-38 years). During follow-up, 2823 individuals developed ischemic stroke and 3792 myocardial infarction. The cumulative incidence of ischemic stroke was similar in individuals with and without FH mutations (P=0.50) (Figure 1) . As a positive control, myocardial infarction was included as an end point, and the cumulative incidence of myocardial infarction was, as expected, higher for individuals with an FH mutation compared to individuals without a mutation (P<0.001). The cumulative incidences of ischemic stroke at age 80 years were 4% and 7% with and without an FH mutation; corresponding incidences of myocardial infarction were 20% and 8%. For the positive control hypertension, individuals with hypertension had higher risk of both ischemic stroke and myocardial infarction compared to individuals without hypertension (both P<0.001).
Results were similar when excluding individuals with diabetes (n=5752) ( Figure II in the online-only Data Supplement).
Risk of Ischemic Stroke by FH Mutations and Clinical Simon Broome, MEDPED, and DLCN Criteria
In prospective observational analyses using FH causative mutations and 3 different clinical criteria for FH,
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104 763 individuals from the CGPS were followed for 578 518 person-years with a median follow-up of 6 years (range: 0 to 11 years), during which time 1554 individuals were diagnosed with ischemic stroke. Using genetics, there was no association between FH and ischemic stroke risk, with a multivariable-adjusted HR for ischemic stroke of 0.42 (95% confidence interval [CI], 0.06-3.01) for mutation carriers compared to noncarriers (Figure 2 ). When using Simon Broome or MEDPED criteria, there was no association between FH and risk of ischemic stroke; using Simon Broome criteria, the HR for ischemic stroke was 1.03 (0.79-1.34) for possible FH; and when using MEDPED criteria, the HR was 1. Similar results were obtained in a sensitivity analysis using a competing risk regression model with death and emigration as competing risks ( Figure III in the online-only Data Supplement). Furthermore, the lack of association between FH by Simon Broome criteria and ischemic stroke was robust across different strata of other risk factors for ischemic stroke ( Figure IV in the online-only Data Supplement). 
Modification of Risk of Ischemic Stroke by Presence of Personal IHD Before Baseline
The main difference between DLCN and MEDPED or Simon Broome FH criteria is the inclusion of a diagnosis of personal premature IHD in DLCN criteria. To test whether this could explain the different results obtained using DLCN criteria showing association with increased ischemic stroke risk, we stratified for IHD before baseline. There was only an association between clinical FH using DLCN criteria and increased risk of ischemic stroke in individuals with IHD before baseline ( Figure 3 ). Also, there was an interaction between FH using DLCN criteria and IHD before baseline on risk of ischemic stroke with a P value for interaction of 0.03.
Risk of Ischemic Stroke by LDL Cholesterol Concentrations in Individuals With and Without IHD Before Baseline
When not taking clinical FH criteria into account and stratifying individuals based only on LDL cholesterol concentrations, very high concentrations of LDL cholesterol ≥5 mmol/L were associated with increased risk of ischemic stroke in individuals with IHD before baseline with a HR of 1.81 (95% CI, 1.03-3.18); however, there was no association in individuals without IHD before baseline (Figure 4) . Also, IHD before baseline was in itself associated with high risk of ischemic stroke with a HR of 1.36 (1.15-1.60) when compared to individuals without IHD before baseline (Figure 4 , top).
Independent Confirmation in the CCHS
Association between FH causative mutations and ischemic stroke risk was independently confirmed in 10 372 individuals from the CCHS. Individuals were followed for 336 408 person-years with a median followup of 37 years (range: 0-38 years), during which time 945 individuals developed ischemic stroke and 1142 a myocardial infarction. In the CCHS, 1 individual was heterozygote for LDLR W23X(rs267607213), 4 heterozygous for LDLR W66G(rs121908025), 1 heterozygote for LDLR W556S, and 12 heterozygous for APOB R3500Q(rs5742904). None was homozygous or compound heterozygous. Similar to results for the CGPS, there was no association between FH mutations and risk of ischemic stroke (P=0.61), but there was a tendency toward increased risk of myocardial infarction in FH mutation carriers, although not statistically significant (P=0.08) (compare Figure 5 to Figure 1 ). The 
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cumulative incidences of ischemic stroke at age 80 years were 6% and 9%, with and without an FH mutation; corresponding incidences were 26% and 11% for myocardial infarction.
Observational and Causal, Genetic Association Between High LDL Cholesterol and Risk of Ischemic Stroke
Association between plasma LDL cholesterol as well as genetically higher LDL cholesterol (using a weighted genotype score) with risk of ischemic stroke was tested in the CGPS and the CCHS combined. Baseline characteristics by weighted genotype score groups are displayed in Table II Based on 104 763 individuals from the Copenhagen General Population Study. The multivariable model was adjusted for age, sex, plasma triglycerides, body mass index, hypertension, systolic blood pressure, diabetes, plasma glucose, atrial fibrillation, lipid-lowering therapy, acetylsalicylic acid therapy, smoking status, cumulative smoking, alcohol consumption, fruit intake, physical activity in leisure time, and income. Diagnosis of clinical FH was based on the DLCN criteria. CI indicates confidence interval; DLCN, Dutch Lipid Clinic Network; FH, familial hypercholesterolemia; and IHD, ischemic heart disease.
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2556] and E670G[rs505151], NPC1L1 -18[rs41279633] and V1296V[rs217434], and HMGCR[rs17238484])
, and with 3190 ischemic strokes and 4199 myocardial infarctions. The observational HR for ischemic stroke for a 1 mmol/L higher plasma concentration of LDL cholesterol was 1.09 (95% CI, 1.05-1.13) while using the weighted genotype score the causal, genetic risk ratio for ischemic stroke for a 1 mmol/L higher LDL cholesterol concentration was 1.11 (0.62-2.02) ( Figure 6 ). As a positive control, corresponding results for myocardial infarction showed increased risk, both observationally and genetically, with a HR of 1.27 (1.22-1.31) for plasma LDL cholesterol, and a causal risk ratio of 1.45 (1.08-1.93) for genetically higher LDL cholesterol.
When examining the risk of ischemic stroke individually in the 5 weighted genotype score groups by multivariable adjusted (age as time scale, sex, lipid-lowering therapy, and date of birth) Cox proportional hazard regression, there was no association between the weighted genotype score for high LDL cholesterol and risk of ischemic stroke (P for trend=0.77) (Figure 7 ).
DISCUSSION
In this study of 106 412 and 10 372 individuals from the general population of Denmark, there was no association between FH mutations (LDLR, APOB) and ischemic stroke risk. In a Mendelian randomization analysis also including common genetic variants, there was no causal effect of high LDL cholesterol on risk of ischemic stroke. Clinical FH based on Simon Broome or MEDPED criteria was also not associated with increased ischemic stroke risk. However, clinical FH according to DLCN criteria was associated with a 2.5-fold higher risk of ischemic stroke, which appeared to be caused by previous personal IHD, rather than by high LDL cholesterol per se. These are novel findings.
A likely explanation for the discrepancy between the findings in this study for the different FH criteria is that personal premature IHD is part of the DLCN criteria, but not part of the MEDPED or Simon Broome criteria. Indeed, individuals with personal IHD at baseline had higher risk of ischemic stroke, compared to individuals without IHD, in all 3 DLCN groups. Furthermore, there was an association between increasing concentrations of LDL cholesterol and increasing risk of ischemic stroke in individuals with personal IHD at baseline, but an association was not found in individuals without IHD at baseline. In addition, FH mutations, not prone to confounding by other risk factors for ischemic stroke, as well as the results from our Mendelian randomization analysis did not indicate a causal association between high LDL cholesterol and increased risk of ischemic stroke. Thus, it is likely that the high risk of ischemic stroke shown using the DLCN criteria is driven by previous personal IHD, which in itself is a risk factor for ischemic stroke. 24 A well-established cause of ischemic stroke is thromboembolisms from the heart or large vessels. 25 A likely simple chain of events could thus be that clinical FH with high LDL cholesterol leads to IHD Figure 4 . Risk of ischemic stroke by baseline ischemic heart disease and by LDL cholesterol concentrations in individuals with and without baseline ischemic heart disease. Based on 104 763 individuals from the Copenhagen General Population Study stratified by ischemic heart disease at baseline and LDL cholesterol concentrations. The multivariable model was adjusted for age, sex, plasma triglycerides, body mass index, hypertension, systolic blood pressure, diabetes, plasma glucose, atrial fibrillation, lipid-lowering therapy, acetylsalicylic acid therapy, smoking status, cumulative smoking, alcohol consumption, fruit intake, physical activity in leisure time, and income. LDL cholesterol concentrations were ×1.43 for individuals using lipid-lowering therapy, corresponding to 30% average reductions due to lipid-lowering therapy. CI indicates confidence interval; IHD, ischemic heart disease; and LDL, low-density lipoprotein. producing mural thrombi from myocardial infarction and heart failure, mural thrombi that will dislodge and cause ischemic stroke. Alternatively, individuals with personal IHD may have a higher burden of atherosclerosis for reasons that are in addition to clinical FH, as for example an accumulation of unhealthy lifestyle factors. LDL cholesterol is traditionally considered a risk factor for ischemic stroke, 26, 27 especially in individuals with previous IHD. 24, 28, 29 However, observational evidence has been conflicting, as some studies have found a positive association between cholesterol concentrations and ischemic stroke risk, [30] [31] [32] while others have not. 18, [33] [34] [35] Randomized clinical trials have shown that lipid-lowering therapy reduces the risk of ischemic stroke in individuals with previous IHD, [36] [37] [38] but this has not been firmly established in individuals without IHD, with some randomized clinical trials finding a reduction in risk of ischemic stroke, 39, 40 and others no reduction in risk. [41] [42] [43] A meta-analysis, including 27 randomized trials investigating lipid-lowering therapy, found that the risk of ischemic stroke was reduced by 21% (95% CI, 15% to 26%) per 1 mmol/L LDL cholesterol reduction. 44 However, it is not clear if this beneficial effect of lipid-lowering therapy on IHD and stroke is exclusively due to LDL cholesterol-lowering effects, or other possible effects of lipid-lowering therapy, like triglyceride lowering. 15, [45] [46] [47] [48] Emerging data suggest that lowering LDL cholesterol increases the risk of diabetes and that having an FH mutation seems to protect against diabetes. 49, 50 As diabetes is a major ischemic stroke risk factor, a likely explanation for a lower than expected risk of ischemic stroke among FH mutation carriers could be lower risk of diabetes; however, when we excluded individuals with diabetes diagnosed before or during follow-up, results still showed no association between FH causative mutations and ischemic stroke, which speaks against lower diabetes prevalence being the explanation of our results.
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Previous studies have provided conflicting results regarding whether FH is associated with high risk of stroke. Four prior studies found no association between FH and the risk of stroke. [8] [9] [10] [11] Mabuchi et al found no difference in the incidence rates of fatal stroke in 15 The causal, genetic estimates are based on individuals from the Copenhagen General Population Study and the Copenhagen City Heart Study combined, with information on all 11 genotypes: LDLR W23X(rs267607213), W66G(rs121908025) and W556S, APOB R3500Q(rs5742904), PCSK9 R46L(rs11591147), R237W(rs148195424), I474V(rs562556) and E670G(rs505151), NPC1L1 -18(rs41279633) and NPC1L1 V1296V(rs217434), and HMGCR(rs17238484). Observational estimates were adjusted for age, sex, plasma triglycerides, body mass index, hypertension, systolic blood pressure, diabetes, plasma glucose, atrial fibrillation, lipid-lowering therapy, smoking status, cumulative smoking, alcohol consumption, physical activity in leisure time, and income. CI indicates confidence interval; and LDL, low-density lipoprotein. However, Kaste and Koivisto found a positive association between clinical FH and ischemic stroke risk comparing the incidence rates in 54 heterozygote FH cases and individuals in the general population in Finland. 12 In that study, approximately 75% of the participants had IHD at baseline, which is in line with our finding that individuals with clinical FH and with previous personal IHD had a high risk of ischemic stroke, while individuals with FH without previous personal IHD did not have a high risk of ischemic stroke.
Strengths of our study include the large number of individuals from the general population, and the use of validated ischemic stroke end points excluding hemorrhagic stroke. Also, we did not lose track of a single individual.
Limitations include lack of information regarding children of participants, tendon xanthomas, and arcus corneae; thus, we were not able to include this in the clinical diagnostic criteria, which possibly may have led to underdiagnosing clinical FH. Also, we only included white adults and, therefore, our findings may not necessarily be applicable to other ethnicities; however, we are not aware of data that suggest the present results should not be applicable to other ethnicities.
LDL cholesterol concentrations were adjusted to reflect a mean 30% reduction in individuals receiving lipid-lowering therapy. This is an oversimplification of the real effect, which varies among individuals and among different statins. In addition, selective prescription of lipid-lowering therapy and other cardiovascular preventive therapies, as well as comprehensive health counseling, in individuals with FH causative mutations could have influenced our findings, as these individuals did not show high risk of ischemic stroke and even showed a trend toward a lower risk of ischemic stroke. If there is no association between LDL cholesterol and risk of ischemic stroke and individuals with FH mutations are more likely to receive treatment for other cardiovascular risk factors, this could lead to a seemingly inverse association between FH mutations and risk of ischemic stroke. An additional limitation includes the fact that we only capture ≈39% of FH mutations in the Copenhagen population, so whether more deleterious mutations, which are rarer, would change the risk prediction is unclear. Also, although we performed multivariable adjustment for a wide variety of risk factors for ischemic stroke, such as lipid-lowering therapy, blood pressure, atrial fibrillation, smoking, and so forth, residual confounding cannot be excluded in the observational studies. Finally, although the sample sizes of the populations are large, due to the statistical power, we cannot fully exclude that there could be a modest positive association between FH and LDL cholesterol and risk of ischemic stroke.
CONCLUSIONS
FH and high LDL cholesterol did not confer an increased risk of ischemic stroke. A positive association with ischemic stroke observed for some clinical FH criteria and high LDL cholesterol appears to be due to previous ischemic heart disease, rather than to high LDL cholesterol per se.
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